UBS AM’s Inhibrx INBX Stock Holding History

UBS AM’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.9M	Buy	20,067 +20,000	+29,851%	+$2M	﹤0.01%	2075
2026 Q1	$4.5K	Buy	67 +57	+570%	+$4.23K	﹤0.01%	3473
2025 Q4	$790	Sell	10 -100	-91%	-$6.81K	﹤0.01%	3208
2025 Q3	$3.71K	Buy	+110	New	+$2.71K	﹤0.01%	2265

Other funds holding INBX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS AM's INBX Position: Q2 2026 in Review

UBS AM increased its Inhibrx (INBX) stake by 29,851% in Q2 2026, buying an estimated $2M and bringing the position to 20,067 shares worth $1.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2075.

UBS AM first reported a position in INBX in Q3 2025 and has held it in 4 quarters since. 163 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

UBS AM held 20,067 shares of Inhibrx worth $1.9M as of Q2 2026.
UBS AM bought 20,000 Inhibrx shares in Q2 2026, an estimated $2M.
Inhibrx made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2075 holding.
UBS AM first reported a position in Inhibrx in Q3 2025 and has held it in 4 quarters since.
163 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.